Straits Times Index
3,301.78 +4.23 (+0.13%) S&P 500
5,483.39 +10.16 (+0.19%) Dow
38,805.43 +27.33 (+0.07%) Nasdaq
17,870.42 +13.40 (+0.08%) Bitcoin USD
64,552.71 -702.46 (-1.08%) CMC Crypto 200
1,347.50 -41.90 (-3.02%)
KRMD Jun 2024 2.500 call
| Previous close | 0.1400 |
| Open | 0.1400 |
| Bid | 0.0000 |
| Ask | 0.2500 |
| Strike | 2.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.1400 - 0.1400 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Business Wire
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
MAINZ, Germany, & MAHWAH, N.J., June 05, 2024--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution. "We want to ensure that medications are safe and easy to use for pa
Business WireKORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
MAHWAH, N.J., June 04, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical’s Freedom Infusion System (the "Freedom System") for an FDA and EMA approved subcutaneous oncolog
- Business Wire
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
MAHWAH, N.J., May 14, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce the signing of a Phase III clinical supply agreement for a novel enzyme replacement therapy to treat a rare endocrinological disease.
